UBS Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-600
| Closed | -$126 | – | 10251 |
|
|
2023
Q2 | $126 | Sell |
600
-52,636
| -99% | -$9.14K | ﹤0.01% | 8472 |
|
|
2023
Q1 | $8.52K | Buy |
53,236
+31,074
| +140% | +$13.8K | ﹤0.01% | 7716 |
|
|
2022
Q4 | $12.4K | Buy |
22,162
+20,769
| +1,491% | +$17.7K | ﹤0.01% | 8277 |
|
|
2022
Q3 | $2K | Sell |
1,393
-8,116
| -85% | -$8.75K | ﹤0.01% | 9845 |
|
|
2022
Q2 | $6K | Buy |
+9,509
| New | +$7.3K | ﹤0.01% | 8777 |
|
|
2022
Q1 | – | Sell |
-6,312
| Closed | -$14K | – | 11231 |
|
|
2021
Q4 | $14K | Sell |
6,312
-10,833
| -63% | -$27.2K | ﹤0.01% | 8385 |
|
|
2021
Q3 | $59K | Buy |
+17,145
| New | +$52.8K | ﹤0.01% | 6207 |
|
|
2021
Q2 | – | Sell |
-1,942
| Closed | -$6K | – | 10015 |
|
|
2021
Q1 | $6K | Buy |
1,942
+805
| +71% | +$2.69K | ﹤0.01% | 8266 |
|
|
2020
Q4 | $2K | Sell |
1,137
-14,324
| -93% | -$23.6K | ﹤0.01% | 8145 |
|
|
2020
Q3 | $18K | Buy |
15,461
+13,530
| +701% | +$13.9K | ﹤0.01% | 6411 |
|
|
2020
Q2 | $2K | Sell |
1,931
-1,698
| -47% | -$1.62K | ﹤0.01% | 7685 |
|
|
2020
Q1 | $3K | Buy |
+3,629
| New | +$4.21K | ﹤0.01% | 7542 |
|
|
2019
Q2 | – | Sell |
-1,526
| Closed | -$3K | – | 8255 |
|
|
2019
Q1 | $3K | Sell |
1,526
-6,012
| -80% | -$8.8K | ﹤0.01% | 7366 |
|
|
2018
Q4 | $9K | Buy |
7,538
+522
| +7% | +$939 | ﹤0.01% | 7302 |
|
|
2018
Q3 | $19K | Buy |
7,016
+5,353
| +322% | +$11.1K | ﹤0.01% | 6833 |
|
|
2018
Q2 | $3K | Buy |
+1,663
| New | +$3.36K | ﹤0.01% | 7669 |
|
|
2018
Q1 | – | Sell |
-100
| Closed | – | – | 8270 |
|
|
2017
Q4 | $0 | Sell |
100
-200
| -67% | -$415 | ﹤0.01% | 8181 |
|
|
2017
Q3 | $0 | Hold |
300
| – | – | ﹤0.01% | 8093 |
|
|
2017
Q2 | $0 | Sell |
300
-200
| -40% | -$386 | ﹤0.01% | 8081 |
|
|
2017
Q1 | $2K | Sell |
500
-15,591
| -97% | -$38.4K | ﹤0.01% | 7321 |
|
|
2016
Q4 | $22K | Buy |
16,091
+15,291
| +1,911% | +$20K | ﹤0.01% | 6464 |
|
|
2016
Q3 | $1K | Sell |
800
-6,269
| -89% | -$9.63K | ﹤0.01% | 7557 |
|
|
2016
Q2 | $9K | Buy |
7,069
+4,769
| +207% | +$22.3K | ﹤0.01% | 6855 |
|
|
2016
Q1 | $12K | Sell |
2,300
-128,764
| -98% | -$788K | ﹤0.01% | 6552 |
|
|
2015
Q4 | $1.03M | Buy |
131,064
+128,639
| +5,305% | +$1.11M | ﹤0.01% | 3387 |
|
|
2015
Q3 | $20K | Buy |
2,425
+674
| +38% | +$6.22K | ﹤0.01% | 6704 |
|
|
2015
Q2 | $19K | Buy |
1,751
+251
| +17% | +$3.22K | ﹤0.01% | 6927 |
|
|
2015
Q1 | $21K | Buy |
1,500
+1,000
| +200% | +$15.3K | ﹤0.01% | 6951 |
|
|
2014
Q4 | $8K | Buy |
+500
| New | +$7.28K | ﹤0.01% | 8625 |
|
Other funds holding INFI
UBS Group's INFI Position: Q3 2023 in Review
UBS Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 600 shares — an estimated $126 sold.
UBS Group first reported a position in INFI in Q4 2014 and held it in 29 quarters. The position peaked at $1.03M in Q4 2015. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.
- UBS Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 600 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $126.
- UBS Group first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 29 quarters.
- UBS Group's Infinity Pharmaceuticals, Inc. position peaked at $1.03M in Q4 2015.
- 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.